ONTOZRY® granted marketing authorisation by European Commission

A new anti-epileptic drug has received marketing authorisation from the European Commission to allow the manufacturers to make the drug available in member states. 

ONTOZRY® (also know as Cenobamate) is a medication indictaed for use in the treatement of drug-resistant focal-onset seizures in adults. 

By received marketing autorisation, this means that the drug's manufacturers can now apply to Irish authorities to make the medication available in this country. We welcome the EU Commission's decision as due to the individual nature of a person's epilepsy, it can be a journey in finding the right treatment suitable to the individual's condition. Therefore, the more options that may be open to clinicians, the better a chance a person with epilepsy may have of gaining control of their condition. 

We have reached out to the manufactuers of ONTOZRY® seeking an update on their plans  with regard to applying to make the drug available in Ireland. As soon as we have an update, we will update our website and social media channels.